Sarepta slides as FDA about-turn on panel clouds gene therapy approval path
By Aditya Samal (Reuters) -Shares of Sarepta Therapeutics Inc slumped as much as 21% on Friday on uncertainty over its gene therapy for Duchenne muscular dystrophy after the U.S. health regulator reversed…